SSR149744C
Phase 2Small molecule
SanofiSSR149744C is one of 10 small molecule programs targeting Ventricular arrhythmia. It is currently in Phase 2.
1
Indications
1
Total Trials
0
Active Trials
9
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
19 competitors in Ventricular Arrhythmia
#DrugCompanyPhaseTrials
1Lipitor
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Xylocaine
MMEDRx USA, Inc.
Approved
Acei/arb
NovartisApproved
Tambocor
AAlvogen Korea
Phase 3
Antiarrhythmic Drugs
NNational Institute of Cardiology, Warsaw, Poland
Approved
Eleclazine
GileadPhase 2
Botulinum Toxin
MMeshalkin Research Institute of Pathology of Circulation
Phase 1
SSR149744C
SanofiPhase 2
S48168
RRyCarma Therapeutics, Inc.
Phase 2
Oral Magnesium Supplement
UUniversity of Minnesota
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for SSR149744C. EMBL-EBI & Wellcome Sanger Institute.
- [4]